Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16126254 | 0.92 | PTGS2 (0.35) | PTGS2PTGS1NR1H2SCN9AHSD11B1 | |
| SCHEMBL16126253 | 0.92 | PTGS2 (0.34) | PTGS2PTGS1NR1H2SCN9ARORC | |
| SCHEMBL16126226 | 0.89 | PTGS2 (0.35) | PTGS2PTGS1NR1H2HSD11B1RORC | |
| SCHEMBL20431132 | 0.89 | PTGS2 (0.36) | PTGS2PTGS1NR1H2KCNH2SCN9A | |
| SCHEMBL16126728 | 0.88 | NR1H2 (0.38) | PTGS2PTGS1NR1H2KCNH2SCN9A | |
| SCHEMBL16126599 | 0.88 | NR1H2 (0.36) | PTGS2PTGS1NR1H2KCNH2SCN9A | |
| SCHEMBL16126355 | 0.87 | PTGS2 (0.36) | PTGS2PTGS1NR1H2HSD11B1RORC | |
| SCHEMBL16126736 | 0.87 | PTGS2 (0.36) | PTGS2PTGS1NR1H2HSD11B1 | |
| SCHEMBL18110476 | 0.86 | PTGS2 (0.35) | PTGS2PTGS1NR1H2SCN9AHSD11B1 | |
| SCHEMBL20431120 | 0.86 | PTGS2 (0.35) | PTGS2PTGS1NR1H2KCNH2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2967073-B9 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-10 | — | — | EP | claimed |
| EP-2967073-B1 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | claimed |
| US-9751869-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-05 | — | — | US | claimed |
| US-20240293401-A1 | COMBINATION THERAPY WITH AN LXR AGONIST AND AN INHIBITOR COMPOUND | Asteroid Therapeutics (US) | 2024-09-05 | — | — | US | disclosed |
| EP-2967073-B9 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-2967073-B9 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-2967073-B1 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2967073-B1 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | disclosed |
| US-9751869-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751869-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751869-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160289222-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289222-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289222-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | US | disclosed |
| WO-2014152738-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289222-A1 | LXR MODULATORS | NR1H2, NR1H3, NR1H4 | PTGS2 1088/4885PTGS1 774/4885NR1H2 1/4885 |
| US-20240293401-A1 | COMBINATION THERAPY WITH AN LXR AGONIST AND AN INHIBITOR COMPOUND | NR1H2, NR1H3, NR1H4 | PTGS2 2899/4885PTGS1 2750/4885NR1H2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.